Scandinavian Biopharma and Neovii extend and expand their distribution agreement for the transplantation product Grafalon
Scandinavian Biopharma Distribution AB has extended and expanded its distribution agreement with Neovii Pharmaceuticals AG. This collaboration involves an extension of the agreement for the immunosuppressive drug Grafalon (anti-human T-lymphocyte immunoglobulin, ATLG) in Sweden, Norway, and Denmark, and now also includes Finland, thus encompassing all the Nordic countries.